RESULTS: The results were obtained after 3 days, the HVs in groups X and E were smaller than those in group S (group X vs S P=0.010(*), group E vs S P=0.002(*), P<0.05). The levels of ALT and AST in group S and X were lower than those in group E (ALT Group S vs E P=0.019(*), group X vs E P=0.003(*), P<0.05; AST group X vs E P=0.002(*), P<0.05). The levels of ALP and
PCNA labeling index in group X were lower than those in group S and E (ALP group X vs S P=0.000(*), group X vs E P=0.000(*). P<0.05;
PCNA group X vs S P=0.008(*), group X vs E P=0.048(*), P<0.05). The levels of
creatinine in group S were lower than those in group E (group S vs E P=0.017, P<0.05). The degree of
tumor necrosis in group S was lower than those in groups X and E (group S vs X P=0.006(*), group S vs E P=0.006(*), P<0.05). After 8 days, the HVs in groups X and E were smaller than those in group S (group X vs S P=0.007(*), group E vs S P=0.004(*), P<0.05). The difference of HVs between groups X and E was not significant. The levels of
albumin, ALT, AST and
creatinine in group X were not higher than those in other groups, the levels of ALP and
PCNA in group X were lower than those in groups S and E (ALP group X vs E P=0.006(*) P<0.05;
PCNA group X vs S P=0.044(*), group X vs E P=0.021(*), P<0.05). The degree of
tumor necrosis in group S was lower than that in groups X and E (group S vs X P=0.001(*), group S vs E P=0.002(*), P<0.05).
CONCLUSION: The therapeutic effectiveness of intra-
tumor injection of XZL and
ethanol on implanted
hepatoma is obvious, but the toxicity of XZL on liver function is markedly lower than that of group E, at the same time XZL can inhibit the growth of
tumor. XZL is relatively better and safer than
ethanol in intra-
tumor injection
therapy.